The ELOC creates a persistent overhang of potential dilution, which will likely pressure the stock price, especially given the company's small $28M market cap relative to the $100M facility. Monitor for SEC effectiveness of the F-1 registration and any draw notices, which would trigger immediate selling by Seven Knots at a discount.
Price Chart
Executive Summary
Optimi Health Corp. entered into an equity line of credit (ELOC) with Seven Knots, LLC, securing the right to sell up to US$100 million of its common shares at a 3% discount to market price, subject to a floor price. The company issued a US$1.5 million convertible promissory note as commitment consideration, with a second US$500,000 note contingent on ELOC draws exceeding US$7 million. This provides a flexible capital source but introduces significant potential dilution and a 2.99% beneficial ownership cap on the investor's conversions, creating a bearish overhang for existing shareholders.
Key Facts
- Optimi Health entered an ELOC with Seven Knots, LLC for up to US$100 million in common shares.
- Shares sold at 97% of the lower of the lowest sale price or VWAP on the purchase date, with a maximum of US$2 million per draw.
- A US$1.5 million convertible promissory note was issued to Seven Knots as commitment consideration, convertible at 95% of the 20-day VWAP (floor US$3.00).
- A second US$500,000 convertible note will be issued if ELOC draws reach US$7 million.
- Seven Knots' beneficial ownership is capped at 2.99% upon conversion of the commitment notes.
- No shares may be sold under the ELOC until the SEC declares the related F-1 registration statement effective.
Financial Impact
Up to US$100 million potential equity issuance at a 3% discount to market, plus up to US$2 million in convertible notes (US$1.5M issued, US$500K contingent) convertible at 95% of VWAP with a US$3.00 floor.
Risk Factors
- Massive dilution risk relative to current market cap ($28M vs $100M ELOC capacity).
- Downward price pressure from shares sold at a 3% discount to market.
- Potential for accelerated selling if the stock price approaches the 85% floor trigger.
- Conversion of commitment notes could add further dilution at a fixed floor price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005754 |
| Document: 0001171843-26-005754-index-headers.html | 0001171843-26-005754 |
| Document: 0001171843-26-005754-index.html | 0001171843-26-005754 |
| Document: 0001171843-26-005754.txt | 0001171843-26-005754 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $3.12 | awaiting T+5 | — | $3.04 (−2.56%) |
Oct 20, 2026 7d ago | 6-K | $3.36 $3.04 | ▼ −9.52% | ▼ −9.60% | $3.04 (−9.52%) |
Oct 7, 2026 20d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.04 (−24.75%) |
Oct 5, 2026 22d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.04 (−26.39%) |
Sep 29, 2026 28d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.04 (−36.40%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.04 (−38.71%) |
Sep 22, 2026 5w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.04 (−38.71%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.04 (−37.96%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.04 (−32.44%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.04 (+37.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers